COVID-19 Disease

24 registered clinical trials studyying COVID-19 Disease.

Status	Trial	Sponsor	Phase
Unknown	A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine NCT05947812	60P Australia Pty Ltd	Phase 2
Completed	ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 NCT05329220	Bavarian Nordic	Phase 3
Completed	Epidemiologic Register on Diabetes and COVID-19 in Tunisia NCT05603130	Les Laboratoires des Médicaments Stériles	—
Unknown	Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronaviru NCT04984408	International Vaccine Institute	Phase 3
Completed	ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects NCT05077267	Bavarian Nordic	Phase 2
Unknown	A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes NCT04969172	Eli Sprecher, MD	Phase 2
Unknown	Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease NCT04779359	Shanghai Public Health Clinical Center	—
Completed	A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1) NCT04830800	Institute of Vaccines and Medical Biologicals, Vietnam	Phase 1
Completed	Tafenoquine in Patients With Mild to Moderate COVID-19 NCT04533347	60 Degrees Pharmaceuticals LLC	Phase 2
Completed	COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection NCT04787510	University Hospital, Ioannina	—
Terminated	Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure NCT04642638	Inovio Pharmaceuticals	Phase 2 / Phase 3
Terminated	Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults NCT04417257	Laurent Pharmaceuticals Inc.	Phase 2 / Phase 3
Completed	Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients NCT04472013	University Hospital, Basel, Switzerland	—
Completed	A Study of LAM-002A for the Prevention of Progression of COVID-19 NCT04446377	OrphAI Therapeutics	Phase 2
Completed	Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU NCT04757792	Benha University	—
Unknown	Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients NCT04522037	Hospices Civils de Lyon	—
Completed	Photobiomodulation Therapy Versus Integrated Myofascial Release Therapy Techniques In Patients With COVID-19 W NCT06795841	Beni-Suef University	N/A
Completed	Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease NCT04603729	Fatima Memorial Hospital	Phase 3
Completed	VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease NCT04587323	University of Alabama at Birmingham	—
Completed	A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Cause NCT04682873	Joint Stock Company "Farmak"	Phase 3
Completed	Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID NCT04359212	Quovadis Associazione	—
Unknown	Outcomes of Covid-19 Protective Measures in Endoscopy NCT04371354	Fundacion Miguel Servet	—
Completed	A Novel Nomogram to Predict Severity of COVID-19 NCT04366024	Xinqiao Hospital of Chongqing	—
Completed	A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease NCT04347369	Xinqiao Hospital of Chongqing	—